|
|
|
| The Application of CRISPR/Cas9 in the Treatment of Human Virus Infection-Related Diseases |
WANG Wei-dong,DU Jia-ru,ZHANG Yun-shang,FAN Jian-ming( ) |
| School of Public Health, Zhengzhou University,Zhengzhou 450001, China |
|
|
|
Abstract Viral infection-related diseases pose a serious threat to human health. Current antiviral therapies cannot cure some diseases caused by chronic viral infections, such as AIDS and hepatitis B. Therefore, new treatment methods are urgently needed. Gene-editing technology that can directly target genetic material may become a powerful tool against viruses. As a new programmable nuclease-mediated gene-editing technology, the CRISPR/Cas9 system has been successfully applied to the research of a variety of human-related diseases due to its high editing efficiency, simple operation, low cost, and wide application range. It also provides new technical means for the research of viral infection-related diseases and the development of new treatment methods. The mechanism of the CRISPR/Cas9 system and the latest advances in the treatment of common human viral infection-related diseases were reviewed in the article.
|
|
Received: 14 September 2020
Published: 14 January 2021
|
|
|
|
Corresponding Authors:
Jian-ming FAN
E-mail: fan5746067@126.com
|
|
|
| [1] |
Mahfouz M M, Li L, Shamimuzzaman M, et al. De novo-engineered transcription activator-like effector (TALE) hybrid nuclease with novel DNA binding specificity creates double-strand breaks. Proc Natl Acad Sci USA, 2011,108(6):2623-2628.
pmid: 21262818
|
|
|
| [2] |
Doudna J A, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science, 2014,346(6213):1258096.
doi: 10.1126/science.1258096
pmid: 25430774
|
|
|
| [3] |
Jansen R, Embden J D, Gaastra W, et al. Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol, 2002,43(6):1565-1575.
doi: 10.1046/j.1365-2958.2002.02839.x
pmid: 11952905
|
|
|
| [4] |
Grissa I, Vergnaud G, Pourcel C. The CRISPRdb database and tools to display CRISPRs and to generate dictionaries of spacers and repeats. BMC Bioinformatics, 2007,8(1):172.
|
|
|
| [5] |
Horvath P, Romero D A, Coûté-Monvoisin A C, et al. Diversity, activity, and evolution of CRISPR loci in Streptococcus thermophilus. Journal of Bacteriology, 2008,190(4):1401-1412.
doi: 10.1128/JB.01415-07
pmid: 18065539
|
|
|
| [6] |
Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 2012,337(6096):816-821.
pmid: 22745249
|
|
|
| [7] |
Makarova K S, Aravind L, Grishin N V, et al. A DNA repair system specific for thermophilic Archaea and bacteria predicted by genomic context analysis. Nucleic Acids Research, 2002,30(2):482-496.
pmid: 11788711
|
|
|
| [8] |
Makarova K S, Haft D H, Barrangou R, et al. Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol, 2011,9(6):467-477.
pmid: 21552286
|
|
|
| [9] |
Garneau J E, Dupuis M è, Villion M, et al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature, 2010,468(7320):67-71.
pmid: 21048762
|
|
|
| [10] |
Deltcheva E, Chylinski K, Sharma C M, et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature, 2011,471(7340):602-607.
pmid: 21455174
|
|
|
| [11] |
Maartens G, Celum C, Lewin S R. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet, 2014,384(9939):258-271.
doi: 10.1016/S0140-6736(14)60164-1
pmid: 24907868
|
|
|
| [12] |
Ebina H, Misawa N, Kanemura Y, et al. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Scientific Reports, 2013,3(1):7.
|
|
|
| [13] |
Chan D C, Kim P S. HIV entry and its inhibition. Cell, 1998,93(5):681-684.
doi: 10.1016/s0092-8674(00)81430-0
pmid: 9630213
|
|
|
| [14] |
Li C, Guan X M, Du T, et al. Inhibition of HIV-1 infection of primary CD4(+) T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9. Journal of General Virology, 2015,96(Pt-8):2381-2393.
|
|
|
| [15] |
Xu L, Yang H, Gao Y, et al. CRISPR/Cas9-mediated CCR5 ablation in human hematopoietic stem/progenitor cells confers HIV-1 resistance in vivo. Molecular Therapy, 2017,25(8):1782-1789.
doi: 10.1016/j.ymthe.2017.04.027
pmid: 28527722
|
|
|
| [16] |
Xiao Q Q, Chen S L, Wang Q K, et al. CCR5 editing by Staphylococcus aureus Cas9 in human primary CD4(+) T cells and hematopoietic stem/progenitor cells promotes HIV-1 resistance and CD4(+) T cell enrichment in humanized mice. Retrovirology, 2019,16:17.
doi: 10.1186/s12977-019-0479-9
pmid: 31242909
|
|
|
| [17] |
Connor R I, Sheridan K E, Ceradini D, et al. Change in coreceptor use correlates with disease progression in HIV-1: infected individuals. The Journal of experimental medicine, 1997,185(4):621-628.
doi: 10.1084/jem.185.4.621
pmid: 9034141
|
|
|
| [18] |
Wang Q K, Chen S L, Xiao Q Q, et al. Genome modification of CXCR4 by Staphylococcus aureus Cas9 renders cells resistance to HIV-1 infection. Retrovirology, 2017,14(1):12.
doi: 10.1186/s12977-017-0338-5
pmid: 28193275
|
|
|
| [19] |
Hou P P, Chen S L, Wang S L, et al. Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. Scientific Reports, 2015,5(1):12.
|
|
|
| [20] |
Liu Z P, Chen S L, Jin X, et al. Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4(+) T cells from HIV-1 infection. Cell and Bioscience, 2017,7(1):15.
doi: 10.1186/s13578-017-0142-x
|
|
|
| [21] |
Trepo C, Chan H L Y, Lok A. Hepatitis B virus infection. Lancet, 2014,384(9959):2053-2063.
doi: 10.1016/S0140-6736(14)60220-8
pmid: 24954675
|
|
|
| [22] |
Maepa M B, Jacobs R, Van Den Berg F, et al. Recent developments with advancing gene therapy to treat chronic infection with hepatitis B virus. Current Opinion in Hiv and Aids, 2020,15(3):200-207.
doi: 10.1097/COH.0000000000000623
pmid: 32141890
|
|
|
| [23] |
Ramanan V, Shlomai A, Cox D B T, et al. CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. Scientific Reports, 2015,5(1):10833.
|
|
|
| [24] |
Wang J, Xu Z W, Liu S, et al. Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication. World Journal of Gastroenterology, 2015,21(32):9554-9565.
doi: 10.3748/wjg.v21.i32.9554
pmid: 26327763
|
|
|
| [25] |
Li H, Sheng C Y, Wang S, et al. Removal of integrated hepatitis B virus DNA using CRISPR-Cas9. Frontiers in Cellular and Infection Microbiology, 2017,7:91.
doi: 10.3389/fcimb.2017.00091
pmid: 28382278
|
|
|
| [26] |
Liu Y, Zhao M X, Gong M X, et al. Inhibition of hepatitis B virus replication via HBV DNA cleavage by Cas9 from Staphylococcus aureus. Antiviral Research, 2018,152:58-67.
doi: 10.1016/j.antiviral.2018.02.011
pmid: 29458131
|
|
|
| [27] |
Song J, Zhang X C, Ge Q Y, et al. CRISPR/Cas9-mediated knockout of HBsAg inhibits proliferation and tumorigenicity of HBV-positive hepatocellular carcinoma cells. Journal of Cellular Biochemistry, 2018,119(10):8419-8431.
pmid: 29904948
|
|
|
| [28] |
Zhou S J, Deng Y L, Liang H F, et al. Hepatitis B virus X protein promotes CREB-mediated activation of miR-3188 and Notch signaling in hepatocellular carcinoma. Cell Death and Differentiation, 2017,24(9):1577-1587.
doi: 10.1038/cdd.2017.87
pmid: 28574502
|
|
|
| [29] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018,68(6):394-424.
doi: 10.3322/caac.21492
pmid: 30207593
|
|
|
| [30] |
Yeo-Teh N S L, Ito Y, Jha S. High-risk human papillomaviral oncogenes E6 and E7 target key cellular pathways to achieve oncogenesis. Int J Mol Sci, 2018,19(6):1706.
doi: 10.3390/ijms19061706
|
|
|
| [31] |
Zhen S, Hua L, Takahashi Y, et al. In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9. Biochemical and Biophysical Research Communications, 2014,450(4):1422-1426.
doi: 10.1016/j.bbrc.2014.07.014
|
|
|
| [32] |
Zhen S, Lu J J, Wang L J, et al. In vitro and in vivo synergistic therapeutic effect of cisplatin with human papillomavirus16 E6/E7 CRISPR/Cas9 on cervical cancer cell line. Translational Oncology, 2016,9(6):498-504.
doi: 10.1016/j.tranon.2016.10.002
pmid: 27816686
|
|
|
| [33] |
Pirouzfar M, Amiri F, Dianatpour M, et al. CRISPR/Cas9-mediated knockout of MLL5 enhances apoptotic effect of cisplatin in HeLa cells in vitro. Excli Journal, 2020,19:170-182.
doi: 10.17179/excli2019-1957
pmid: 32194363
|
|
|
| [34] |
Zhong S, Zhang Y, Yin X, et al. CDK7 inhibitor suppresses tumor progression through blocking the cell cycle at the G2/M phase and inhibiting transcriptional activity in cervical cancer. Oncotargets and Therapy, 2019,12:2137-2147.
doi: 10.2147/OTT
|
|
|
| [35] |
Ling K, Yang L, Yang N, et al. Gene targeting of HPV18 E6 and E7 synchronously by nonviral transfection of CRISPR/Cas9 system in cervical cancer. Human Gene Therapy, 2020,31(5-6):297-308.
doi: 10.1089/hum.2019.246
pmid: 31989837
|
|
|
| [36] |
Van Diemen F R, Kruse E M, Hooykaas M J G, et al. CRISPR/Cas9-mediated genome editing of herpesviruses limits productive and latent infections. Plos Pathogens, 2016,12(6):29.
|
|
|
| [37] |
Turner E M, Brown R S H, Laudermilch E, et al. The Torsin activator LULL1 is required for efficient growth of herpes simplex virus 1. Journal of Virology, 2015,89(16):8444-8452.
doi: 10.1128/JVI.01143-15
pmid: 26041288
|
|
|
| [38] |
Roehm P C, Shekarabi M, Wollebo H S, et al. Inhibition of HSV-1 replication by gene editing strategy. Scientific Reports, 2016,6(5457):23146.
|
|
|
| [39] |
Latif M B, Raja R, Kessler P M, et al. Relative contributions of the cGAS-STING and TLR3 signaling pathways to attenuation of herpes simplex virus 1 replication. Journal of Virology, 2020,94(6):e01717-19.
doi: 10.1128/JVI.01717-19
pmid: 31896590
|
|
|
| [40] |
Young L S, Rickinson A B. Epstein-Barr virus: 40 years on. Nat Rev Cancer, 2004,4(10):757-768.
doi: 10.1038/nrc1452
pmid: 15510157
|
|
|
| [41] |
Su S, Zou Z, Chen F, et al. CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer. Oncoimmunology, 2017,6(1):e1249558.
doi: 10.1080/2162402X.2016.1249558
pmid: 28197365
|
|
|
| [42] |
Yuen K S, Wang Z M, Wong N H M, et al. Suppression of Epstein-Barr virus DNA load in latently infected nasopharyngeal carcinoma cells by CRISPR/Cas9. Virus Research, 2018,244:296-303.
doi: 10.1016/j.virusres.2017.04.019
pmid: 28456574
|
|
|
| [43] |
Huo H, Hu G. CRISPR/Cas9-mediated LMP1 knockout inhibits Epstein-Barr virus infection and nasopharyngeal carcinoma cell growth. Infectious Agents and Cancer, 2019,14(4):30.
doi: 10.1186/s13027-019-0246-5
|
|
|
| [44] |
Janoly-Dumenil A, Rouvet I, Bleyzac N, et al. A pharmacodynamic model of ganciclovir antiviral effect and toxicity for lymphoblastoid cells suggests a new dosing regimen to treat cytomegalovirus infection. Antimicrobial Agents and Chemotherapy, 2012,56(7):3732-3738.
doi: 10.1128/AAC.06423-11
pmid: 22526305
|
|
|
| [45] |
King M W, Munger J. Editing the human cytomegalovirus genome with the CRISPR/Cas9 system. Virology, 2019,529:186-194.
doi: 10.1016/j.virol.2019.01.021
pmid: 30716580
|
|
|
| [46] |
Gergen J, Coulon F, Creneguy A, et al. Multiplex CRISPR/Cas9 system impairs HCMV replication by excising an essential viral gene. PLoS One, 2018,13(2):e0192602.
doi: 10.1371/journal.pone.0192602
pmid: 29447206
|
|
|
| [47] |
Tai-Schmiedel J, Karniely S, Lau B, et al. Human cytomegalovirus long noncoding RNA4.9 regulates viral DNA replication. PLoS Pathogens, 2020,16(4):e1008390.
doi: 10.1371/journal.ppat.1008390
pmid: 32294138
|
|
|
| [48] |
He M, Yuan H, Tan B, et al. SIRT1-mediated downregulation of p27(Kip1) is essential for overcoming contact inhibition of Kaposi’s sarcoma-associated herpesvirus transformed cells. Oncotarget, 2016,7(46):75698-75711.
doi: 10.18632/oncotarget.12359
pmid: 27708228
|
|
|
| [49] |
Tso F Y, West J T, Wood C. Reduction of kaposi’s sarcoma-associated herpesvirus latency using CRISPR-Cas9 to edit the latency-associated nuclear antigen gene. Journal of Virology, 2019,93(7):e02183-18.
doi: 10.1128/JVI.02183-18
pmid: 30651362
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
